Virological failure rates and HIV-1 drug resistance patterns in patients on first-line antiretroviral treatment in semirural and rural Gabon

Journal of the International AIDS Society

Volumn 15, Issue 2, 2012, Pages

  Liégeois, Florian ^a,b   Vella, Caroline ^a   Eymard Duvernay, Sabrina ^b   Sica, Jeanne ^c   Makosso, Laurent ^a   Mouinga Ondémé, Augustin ^a   Mongo, Arnaud Delis ^c   Boué, Vanina ^a   Butel, Christelle ^b   Peeters, Martine ^b   Gonzalez, Jean Paul ^a   Delaporte, Eric ^b   Rouet, François ^a  

^a CENTRE INTERNATIONAL DE RECHERCHES MÉDICALES DE FRANCEVILLE   (Gabon)

^b INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^c Centre de Traitement Ambulatoire (CTA)   (Gabon)

Author keywords

Africa; Antiretroviral therapy; HIV; Resistance; Viral load

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; THYMIDINE DERIVATIVE; VIRUS RNA; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDY; DRUG TREATMENT FAILURE; FEMALE; GABON; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RURAL AREA; RURAL HEALTH CARE; TREATMENT DURATION; VIROLOGICAL FAILURE; VIRUS LOAD; WORLD HEALTH ORGANIZATION; DRUG EFFECT; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIDDLE AGED; MUTATION; RISK FACTOR; RURAL POPULATION; VIROLOGY;

ADULT; ANTI-HIV AGENTS; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; GABON; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; RISK FACTORS; RURAL POPULATION;

EID: 84877265702     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.15.2.17985     Document Type: Article

References (34)

1. Lawn SD, Harries AD, Wood R. Strategies to reduce early morbidity and mortality in adults receiving antiretroviral therapy in resource-limited settings. Curr Opin HIV AIDS. 2010;5:18-26.
2. Barth RE, Tempelman HA, Moraba R, Hoepelman AI. Long-Term Outcome of an HIV-Treatment Programme in Rural Africa: Viral Suppression despite Early Mortality. AIDS Res Treat. 2011;2011:434375.
3. Bennett DE, Bertagnolio S, Sutherland D, Gilks CF. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther. 2008;13(Suppl. 2):1-13.
4. Jordan MR, Bennett DE, Wainberg MA, Havlir D, Hammer S, Yang C, et al. Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011. Clin Infect Dis. 2012;54(Suppl. 4):S245-9.
5. Caron M, Makuwa M, Souquiere S, Descamps D, Brun Vezinet F, Kazanji M. Human immunodeficiency virus type 1 seroprevalence and antiretroviral drug resistance-associated mutations in miners in Gabon, central Africa. AIDS Res Hum Retroviruses. 2008;24:1225-8.
6. Ndong GP, Adam G, Mouala C, Faucherre V, Kouely PN, Sibeoni J, Courpotin C. National coordination of the ambulatory treatment centers (ATC) in Gabon: a new process to conduct the scaling up of care for people living with HIV-AIDS. Sante. 2008;18:97-102.
7. Walensky RP, Wood R, Ciaranello AL, Paltiel AD, Lorenzana SB, Anglaret X, et al. Scaling up the 2010 World Health Organization HIV treatment guidelines in resource-limited settings: a model-based analysis. PLoS Med. 2010;7:e1000382.
8. Barth RE, van der Loeff MFS, Schuurman R, Hoepelmon AIM, Wensing AMJ, et al. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis. 2010;10:155-66.
9. Vallari A, Holzmayer V, Harris B, Yamaguchi J, Ngansop C, Makamche F, et al. Confirmation of putative HIV-1 group P in Cameroon. J Virol. 2011;85:1403-7.
10. Liégeois F, Boué V, Mouinga-Ondémé A, Kenfack D, Sica J, Rouet F. Suitability of an open automated nucleic acid extractor for high-throughput plasma HIV-1 RNA quantitation in Gabon (central Africa). J Virol Methods. 2012;179:269-71.
11. World Health Organization. Towards universal access: scaling up the priority HIV/AIDS interventions in the health sector. World Health Organization, Geneva, 2010. http://www.who.int/hiv/pub/2010progressreport/summary-en.pdf.
12. Vergne L, Diagbouga S, Kouanfack C, Aghokeng A, Butel C, Laurent C, et al. HIV-1 drug-resistance mutations among newly diagnosed patients before scaling-up programmes in Burkina Faso and Cameroon. Antivir Ther. 2006;11:575-9.
13. Descamps D, Delaugerre C, Masquelier B, Ruffault A, Marcellin AG, Izopet J, et al. Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance. J Med Virol. 2006;78:153-60.
14. Ramadhani HO, Thielman NM, Landman KZ, Ndosi EM, Gao F, Kirchherr JL, et al. Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania. Clin Infect Dis. 2007;45:1492-8.
15. Marconi VC, Sunpath H, Lu Z, Gordon M, Koranteng Apeagyei K, et al. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis. 2008;46:1589-97.
16. Barth RE, Wensing AM, Tempelman HA, Moraba R, Schuurman R, Hoepelman AI. Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated resistance: evidence of transmitted resistance in rural South Africa. AIDS. 2008;22:2210-2.
17. Hosseinipour MC, van Oosterhout JJ, Weigel R, Phiri S, Kamwendo D, Parkin N, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS. 2009;23:1127-34.
18. Dlamini JN, Hu Z, Ledwaba J, Morris L, Maldarelli FM, Dewar RL, et al. Genotypic resistance at viral rebound among patients who received lopinavir/ritonavir- or efavirenz-based first antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2011;58:304-8.
19. Charpentier C, Talla F, Nguepi E, Si-Mohamed A, Belec L. Virological failure and HIV type 1 drug resistance profiles among patients followed-up in private sector, Douala, Cameroon. AIDS Res Hum Retroviruses. 2011;27:221-30.
20. Dagnra AY, Vidal N, Mensah A, Patassi A, Aho K, Salou M, et al. High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. J Int AIDS Soc. 2011;14:30.
21. Muwonga J, Edidi S, Butel C, Vidal N, Monleau M, Okenge A, et al. Resistance to antiretroviral drugs in treated and drug-naive patients in the Democratic Republic of Congo. J Acquir Immune Defic Syndr. 2011;57(Suppl. 1):S27-33.
22. Hamers RL, Sigaloff KC, Wensing AM, Wallis CL, Kityo C, Siwale M, et al. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. Clin Infect Dis. 2012;54:1660-9.
23. Kranzer K, Lewis JJ, Ford N, Zeinecker J, Orrell C, Lawn SD, et al. Treatment interruption in a primary care antiretroviral therapy program in South Africa: cohort analysis of trends and risk factors. J Acquir Immune Defic Syndr. 2010;55:e17-23.
24. Yerly S, Fagard C, Gunthard HF, Hirschel B, Perrin L. Drug resistance mutations during structured treatment interruptions. Antivir Ther. 2003;8:411-5.
25. Ruiz L, Paredes R, Gomez G, Romeu J, Domingo P, Perez Alvarez N, et al. Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients. AIDS. 2007;21:169-78.
26. Danel C, Moh R, Chaix ML, Gabillard D, Gnokoro J, Diby CJ, et al. Two-months-off, four-months-on antiretroviral regimen increases the risk of resistance, compared with continuous therapy: a randomized trial involving West African adults. J Infect Dis. 2009;199:66-76.
27. Luebbert J, Tweya H, Phiri S, Chaweza T, Mwafilaso J, Hosseinipour MC, et al. Virological failure and drug resistance in patients on antiretroviral therapy after treatment interruption in Lilongwe, Malawi. Clin Infect Dis. 2012;55:441-8.
28. Mintsa Ndong A, Caron M, Plantier JC, Makuwa M, Le Hello S, Courgnaud V, et al. High HIV type 1 prevalence and wide genetic diversity with dominance of recombinant strains but low level of antiretroviral drug-resistance mutations in untreated patients in northeast Gabon, central Africa. AIDS Res Hum Retroviruses. 2009;25:411-8.
29. Caron M, Etenna Lekana-Douki S, Makuwa M, Obiang-Ndong GP, Biba O, Nkoghe D, et al. Prevalence, genetic diversity and antiretroviral drugs resistance-associated mutations among untreated HIV-1-infected pregnant women in Gabon, central Africa. BMC Infect Dis. 2012;12:64.
30. Gupta RK, Hill A, Sawyer AW, Cozzi-Lepri A, von Wyl V, Yerly S, et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis. 2009;9:409-17.
31. Sigaloff KC, Hamers RL, Wallis CL, Kityo C, Siwale M, Ive P, et al. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr. 2011;58:23-31.
32. Sigaloff KC, Ramatsebe T, Viana R, de Wit TF, Wallis CL, Stevens WS. Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. AIDS Res Hum Retroviruses. 2012;28:171-5.
33. Wallis CL, Papathanasopolous MA, Fox M, Conradie F, Ive P, Orrell C, et al. Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy. Antivir Ther. 2012;17:313-20.
34. Hamers RL, Wensing AM, Back NK, Arcilla MS, Frissen JP. Multi-nucleoside reverse transcriptase inhibitor resistant HIV type-1 in a patient from Sierra Leone failing stavudine, lamivudine and nevirapine. Antivir Ther. 2011; 16:115-8.